Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.40 |
| ▸ | CPA3 | P15088 | 2/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 9/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266200 | 0.81 | MME (0.40) | CPA1MME | |
| SCHEMBL4264235 | 0.72 | MME (0.41) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL393002 | 0.61 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL1915564 | 0.61 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL5688996 | 0.61 | CPA1 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL4664822 | 0.61 | CYP1A2 (1.00) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL3421012 | 0.60 | CPA1 (0.96) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL27663690 | 0.60 | CPA1 (0.58) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL22115491 | 0.59 | CYP1A2 (0.95) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL9622038 | 0.59 | CYP1A2 (0.86) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082392-A1 | Substituted Carboxylic Acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2009-03-26 | — | — | US | claimed |
| JP-2006525329-A | — | — | 2006-11-09 | — | — | JP | claimed |
| EP-1620420-A2 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | claimed |
| WO-2004099168-A2 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1620420-A2 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004099168-A2 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082392-A1 | Substituted Carboxylic Acids | PTPRJ, PTPRS, PTPRG | CPA1 1736/4885CPA3 3626/4885CPB1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.